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license (http://creativeAlzheimer’s disease relates to brain morphometric measures and cognition. Existing investigations
in this area have been primarily conducted in older cognitively normal (CN) individuals. Therefore,
not much is known about the associations between Ab burden, cortical thickness, and cognition
in midlife. We examined this question in 109, CN, late to middle-aged adults (mean
age5 60.726 5.65 years) from theWisconsin Registry for Alzheimer’s Prevention. They underwent
Pittsburgh Compound B (PiB) and anatomical magnetic resonance (MR) imaging, and a comprehen-
sive cognitive examination. Blinded visual rating of the PiB scans was used to classify the participants
as Ab1 or Ab2. Cortical thickness measurements were derived from the MR images. The Ab1
group exhibited significant thinning of the entorhinal cortex and accelerated age-associated thinning
of the parahippocampal gyrus compared with the Ab2 group. The Ab1 group also had numerically
lower, but nonsignificant, test scores on all cognitivemeasures, and significantly faster age-associated
cognitive decline on measures of Speed & Flexibility, Verbal Ability, and Visuospatial Ability. Our
findings suggest that early Ab aggregation is associated with deleterious changes in brain structure
and cognitive function, even in midlife, and that the temporal lag between Ab deposition and the
inception of neurodegenerative/cognitive changes might be narrower than currently thought.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
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Recent research has indicated the existence of a preclin-
ical stage of Alzheimer’s disease (AD) during which patho-uthor. Tel.: 11-608-265-4479; Fax: 11-608-265-
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commons.org/licenses/by-nc-nd/4.0/).logical changes gradually accumulated in the absence of
detectable cognitive symptoms [1]. Converging evidence
suggests that one of the earliest brain changes seen during
this preclinical stage is an increase in brain amyloid b
(Ab) deposition [1–3]. This Ab deposition begins several
years before the onset of symptoms and continues to
increase as the disease progresses before it approaches aimer’s Association. This is an open access article under the CC BY-NC-ND
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[1,4–6].
Another observable feature of the preclinical stage of AD
is an alteration in brain structure that, among other neurode-
generative effects, leads to reduced cortical thickness [7].
Automated measurement of cortical thickness from anatom-
ical magnetic resonance imaging (MRI) scans is possible
with the use of computer-aided techniques [8,9]. Recently,
studies have explored the connection between Ab
deposition and cortical thickness in preclinical AD using
positron emission tomography (PET) tracers for Ab, such
as Pittsburgh Compound B (PiB). For example, in a study
of older cognitively normal (CN) individuals, Becker and
colleagues [10] found that Ab deposition is associated
with regional cortical thinning especially in posteromedial
and lateral parietal structures. Similarly, Dore and col-
leagues [11] found that an increase in Ab accumulation
was associated with decreased cortical thickness in the pos-
terior cingulate, precuneus, and hippocampus among CN in-
dividuals. Other studies using cerebrospinal fluid (CSF)
biomarkers for Ab have found similar associations between
Ab aggregation and structural brain changes in AD-
susceptible regions [12]. Relatedly, although AD is charac-
terized by a decline in cognition [1], the extent to which
Ab accumulation correlates with cognition among CN indi-
viduals is yet to be fully elucidated. Some investigations into
the effect of Ab on cognition among CN individuals find no
associations [13–15], whereas others do reveal associations,
largely in the domain of episodic memory [16,17].
Most of the research on Ab-related cortical thinning and
cognitive dysfunction has focused on older CN individuals.
Therefore, the manner and extent to which Ab deposition af-
fects brain structure and cognition in midlife remains rela-
tively unexplored. This is an important knowledge gap
because midlife is arguably when AD-related markers of
Ab, brain structure, and cognition are starting to be dynamic.Table 1
Characteristics of study participants*
Variable Ab2, n 5 74 Ab1, n 5 35 P value
FH positive, % 70.3 82.9 .160
APOE ε4 positive, % 35.1 54.3 .058
Non-Hispanic white, % 95.8 94.3 .722
Female, % 55.4 77.1 .029
Age 59.51 (5.82) 63.27 (4.35) ,.001
Education 15.89 (2.37) 16.57 (2.34) .164
MMSE 29.15 (1.05) 29.17 (1.34) .945
IQCODE 46.59 (6.28) 47.66 (5.86) .405
Interval between brain scan
and cognitive assessment,
months
6.58 (6.03) 6.64 (5.92) .961
Abbreviations: Ab, amyloid b; FH, family history of Alzheimer’s disease;
APOE ε4, the 34 allele of the apolipoprotein E gene; MMSE, Mini-Mental
State Examination; IQCODE, Informant Questionnaire on Cognitive
Decline in the Elderly.
*All values are mean (standard deviation) except where otherwise
indicated.Accordingly, in this study we sought to determine how Ab
accumulation relates to cognitive function and structural
changes in AD-relevant brain regions among late to
middle-aged adults at risk for AD. We investigated both
the main effect of Ab burden and its potential acceleration
of normal age-associated alterations in our brain and cogni-
tive outcome measures.2. Materials and methods
2.1. Participants
Participants were recruited from the Wisconsin Registry
for Alzheimer’s Prevention (WRAP) cohort into this neuro-
imaging study. The WRAP is a longitudinal registry of
approximately 1500 late to middle-aged adults who were
cognitively healthy and between the ages 40 and 65 years
at study entry [18]. One hundred and nine consecutive partic-
ipants were selected based on Ab2 or Ab1 rating in their
PiB-PET scan (see section 2.2.2) and also having a usable
MRI scan. They constitute a subset of the individuals
described in an earlier report from our group [19]. Mean
age of the sample at time of brain scan was 60.72 6 5.65
and 62.4% were female. The sample was enriched with per-
sons with a parental family history (FH) of AD (74.3%) and
those positive for the apolipoprotein E ε4 allele (APOE ε4)
(41.3%). The method for determining FH of AD has been
described previously [18]. Study exclusion criteria included
MRI contraindications, major neurological disorder (e.g.,
head trauma with loss of consciousness, neoplasms, and
seizure disorders), current major psychiatric disease (e.g.,
schizophrenia), and abnormal MRI findings (e.g., ventricu-
lomegaly). Table 1 summarizes participants’ background
characteristics. The University of Wisconsin Institutional
Review board approved all study procedures and each sub-
ject provided signed informed consent before participation.
2.2. Neuroimaging protocol2.2.1. PET-PiB protocol
PiB data were acquired with a 70-minute dynamic acqui-
sition followed by reconstruction using a filtered back-
projection algorithm. Data were corrected for random
events, attenuation of annihilation radiation, dead time,
scanner normalization, and scatter radiation, then realigned
and coregistered using SPM 8 (www.fil.ion.ucl.ac.uk/spm).
Finally, the images were transformed into voxel-wise distri-
bution volume ratio (DVR) maps of PiB binding using the
time activity curve of cerebellar gray matter (GM) as the
reference region. More detailed descriptions of PiB radio-
chemical synthesis, PiB-PET scanning, and DVR map gen-
eration may be found in a previous publication [19].
2.2.2. Qualitative PiB rating
To enhance the potential clinical applicability and allow
for the possibility of regional heterogeneity in Ab deposition
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a qualitative approach was adopted for ascertaining cerebral
amyloidosis. Specifically, after achieving high inter- and in-
trareliability between two raters on a subset of PiB images
(blinded to all pertinent subject characteristics such as age,
sex, FH, APOE ε4 status, and cognitive function), a similarly
blinded single rater visually rated all DVRmaps on the inten-
sity and pattern of cortical amyloid binding as described pre-
viously [19]. Of the 109 subjects who provided data for our
analyses, 74 were classified as amyloid negative (Ab2)
and 35 were classified as amyloid positive (Ab1). An
Ab2 rating was given when the scan demonstrates no
cortical amyloid burden or only nonsignificant patchy/diffuse
cortical GM binding not resembling an AD pattern. In
contrast, an Ab1 classification indicated that there was un-
ambiguous GM amyloid binding in at least three cortical
lobes resembling an AD disease pattern.
For descriptive purposes (and to perhaps provide some
basis for comparison with studies that use quantitative cut-
points for Ab positivity) we fitted a receiver operating char-
acteristic (ROC) curve with DVR data sampled bilaterally
from the precuneus—a known inception site for Ab aggrega-
tion [1,20]—as the predictor and Ab rating as the outcome.
This analysis revealed an area under the ROC curve (95%
confidence interval) of 0.993 (0.979, 1.00) for
discriminating Ab2 and Ab1 participants. A DVR cut-
point of 1.10 yielded a sensitivity of 0.971 and a specificity
of 0.973 for distinguishing both groups.
2.2.3. MRI protocol
TheMRI scanswere acquired in the axial plane on aGE!
750 3.0 T scanner with an eight channel phased array head
coil (General Electric, Waukesha, WI). Three-dimensional
T1-weighted inversion recovery-prepared SPGR (spoiled
gradient) scans were collected using the following parame-
ters: inversion time/echo time/repetition time 5 450 ms/
3.2 ms/8.2 ms, flip angle 5 12, slice thickness 5 1 mm no
gap, field of view 5 256, matrix size 5 256! 256! 156.
2.2.4. Automated MRI image analysis
Thickness of cortical structures and volume of subcor-
tical structures were obtained for select regions of interest
(ROIs) using the FreeSurfer image analysis suite version
5.1.0 (http://surfer.nmr.mgh.harvard.edu/) [8,9]. Briefly, the
T1 MRI images were skull stripped and transformed into
Talairach space. Then, using a standard atlas, the images
are segmented, and volumes of subcortical regions, e.g.,
the hippocampus and amygdala, were obtained via this
segmentation. Next, cortical surface meshes were created,
defined as the gray/white matter boundary (the white
matter surface) and the gray/CSF boundary (the pial
surface). After topology correction and deformation of the
surface meshes, the surfaces were parcellated based on a
template atlas. Cortical thickness measurements were
obtained by calculating the distance along a normal vector
from each vertex in the white matter surface to the pialsurface. The thickness values at each vertex within an ROI
were averaged to obtain the ROI measurements. We
focused on eight medial temporal and posteromedial
cortex ROIs in this study. These ROIs were chosen
because of their involvement in the AD cascade. Cortical
thickness measurements were obtained from the entorhinal
cortex, parahippocampal gyrus, fusiform gyrus, cingulate
isthmus, posterior cingulate, and the precuneus, whereas
volumetric measurements were obtained from the
hippocampus and amygdala. Measurements were averaged
across hemispheres to obtain a single value for each ROI.
Although the FreeSurfer automated procedure is 100%
reproducible, user inspection and iterative control point edit-
ing are often required for maximal performance accuracy,
and thus was implemented in this study to ensure proper
cortical reconstruction. In our hands, intra- and interrater reli-
ability is excellent (intraclass correlation coefficient. 0.99),
based on a training sample of 10 brains of varying age and
scan quality, rated by three technicians twice in blind fashion.2.3. Neuropsychological assessment
All 109 participants completed a comprehensive neuro-
psychological battery [18] that included the Mini-Mental
State Examination and other psychometric measures that
span traditional cognitive domains of memory, attention,
executive function, language, and visuospatial ability.
Earlier factor analytic studies of the psychometric mea-
sures within the larger WRAP cohort [21,22] showed that
these tests map onto six cognitive factors: Immediate
Memory, Verbal Learning & Memory, Working Memory,
Speed & Flexibility, Visuospatial Ability, and Verbal
Ability. The individual tests which loaded onto these
factors were as follows: Immediate Memory: Rey
auditory verbal learning test (RAVLT) Trials 1 and 2
[23]; Verbal Learning & Memory: RAVLT Trials 3 to 5
and Delayed Recall Trial [23]; Working Memory: Digit
Span and Letter-Numbering Sequencing subtests from the
Wechsler Adult Intelligence Scale—3rd edition [24];
Speed & Flexibility: Stroop Test interference trial [25],
and Trail Making Test A and B [26]; Visuospatial Ability:
Block Design and Matrix Reasoning subtests from the
Wechsler Abbreviated Scale of Intelligence (WASI) [27]
and Benton Judgment of Line Orientation [28]; Verbal
Ability: Vocabulary and Similarities subtests from the
WASI [27], Boston Naming Test [29], and Reading subtest
from the Wide-Range Achievement Test, 3rd edition [30].
These factor scores were used in our evaluation of the asso-
ciation between Ab retention and cognition in this study.
The mean interval between brain scan and neuropsycholog-
ical assessment was 6.60 6 5.97 months.2.4. Statistical analyses
Group differences on background characteristics were
analyzed using either t-tests or chi-square tests as
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covariance (ANCOVAs) to investigate the main effect of am-
yloid burden (Ab1 vs. Ab2) on ROI measures of brain
structure. For the hippocampus and amygdala, an additional
adjustment was made for intracranial volume. To investigate
whether Ab induces an acceleration of age-associated struc-
tural brain changes, we fitted a series of multiple regression
models that controlled for age and sex, while testing for in-
teractions between age and Ab rating. Where significant,
these interactions would indicate a differential effect of ag-
ing on brain structure among Ab1 subjects compared with
Ab2 subjects.
Analyses of the relationship between amyloid burden and
cognitive function were conducted in the same manner as
those for brain structure. That is, age-, sex-, and education-
adjusted ANCOVAs were used to investigate the main effect
of amyloid burden (i.e., Ab1 vs. Ab2) on the cognitive fac-
tors, whereas age-, sex-, and education-adjusted multiple
regression models, that included age*Ab rating interactions,
were used to investigate whether age-related cognitive
decline is more pronounced among Ab1 individuals. All an-
alyses were performed using SPSS 21.0 (IBM Corp., Ar-
monk, NY), and only findings that met an alpha threshold
of 0.05 (two-tailed) were deemed significant.3. Results
3.1. Subject characteristics
The Ab2 and Ab1 groups differed in age and sex, and
these variables were included as covariates in our analyses.
As expected, there was a tendency for APOE ε41 persons
to be disproportionally represented within the Ab1 group,
although this was nonsignificant. The groups did not differ
in any other background characteristics, including the time
interval between brain and cognitive assessment. These find-
ings are shown in Table 1.3.2. Ab and brain structure
Table 2 summarizes our analyses of the main effect of Ab
burden on brain structure. The Ab1 group exhibited signif-Table 2
Main effect of Ab on brain structure*,y
Region Ab2, n 5 74 Ab1, n 5 35 P value
Entorhinal 3.47 (0.03) 3.32 (0.05) .017
Parahippocampal 2.65 (0.03) 2.71 (0.04) .266
Fusiform 2.62 (0.02) 2.62 (0.02) .988
Cingulate isthmus 2.49 (0.02) 2.51 (0.03) .615
Posterior cingulate 2.63 (0.02) 2.58 (0.03) .175
Precuneus 2.41 (0.01) 2.37 (0.02) .128
Hippocampus 3955.33 (44.74) 3871.82 (66.03) .315
Amygdala 1649.71 (25.20) 1596.95 (37.19) .260
Abbreviation: Ab, amyloid b.
*All values are estimated mean (standard error), adjusted for age and sex.
yAll values are thicknesses (in mm) except for hippocampus and amyg-
dala, which are volumes in mm3.icant cortical thinning in the entorhinal cortex compared
with the Ab2 group. There were no group differences in
any other ROIs examined.
As a secondary analysis, we examined whether local am-
yloid burden is correlated with colocalizedmeasures of brain
structure using Pearson correlations. For this, FreeSurfer
was used to extract mean PiB retention values within each
of the eight ROIs by coregistering each participant’s DVR
image to their FreeSurfer-rendered T1 volume, and then us-
ing FreeSurfer’s automatic cortical parcellation (APARC)1
automatic segmentation (ASEG) template as a mask for ex-
tracting mean PiB values in the ROIs. Correlations were con-
ducted using bilateral measures obtained by averaging ROI
values across hemispheres. Consistent with the group ana-
lyses shown in Table 2, we found that higher entorhinal cor-
tex Ab accumulation was correlated with decreased
entorhinal cortical thickness (r (107) 5 20.22, P 5.020).
We also found a significant association between increased
amygdala Ab burden and decreased amygdala volume (r
(107) 5 20.23, P 5.016). Although the remaining correla-
tions were all in the expected negative direction (i.e., higher
Ab being associated with reduced thickness/volume), they
failed to meet our threshold for statistical significance
(Ps ..1). These results are plotted in Fig. 1.
Our analyses of the impact of Ab burden on age-related
structural changes revealed a trend for the Ab1 group to
have more pronounced age-associated thinning of the para-
hippocampal gyrus compared with the Ab2 group (age*Ab
rating P 5.059). Although none of the other ROIs were sig-
nificant (age*Ab rating Ps ..1), the beta coefficient for the
age*Ab rating term was negative in virtually all analyses,
indicating a similar acceleration of age-associated thinning
within the Ab1 group. These findings are plotted in Fig. 2.3.3. Ab and cognition
Results of the main effect of Ab on cognition are summa-
rized in Table 3. The Ab1 group exhibited numerically
lower scores on all six cognitive factors relative to the
Ab2 group. However, these differences did not meet our cri-
terion for statistical significance (Ps ..1). With respect to
the Ab-induced acceleration of age-related cognitive
decline, we found that Ab1 participants demonstrated
significantly greater age-associated cognitive decline on
Speed & Flexibility (age*Ab rating P 5.034), and also
showed trends for a faster rate of age-associated cognitive
decline on Verbal Ability and Visuospatial Ability (age*Ab
rating Ps 5.058 and .089, respectively). These results are
shown in Fig. 3.4. Discussion
In this study, we examined the relationship between Ab
burden, structural brain changes, and cognitive function
among CN, late to middle-aged adults at risk for AD. We
found that global Ab burden was associated with cortical
Fig. 1. Correlations between amyloid beta (Ab) burden and colocalized magnetic resonance imaging (MRI) measures. The plots depict correlations between
regional cortical thickness and Pittsburgh Compound B (PiB) binding extracted from the same brain region.
B.M. Doherty et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 160-169164thinning in the entorhinal cortex. Thickness of the entorhinal
cortex was also negatively correlated with colocalized PiB
retention, further strengthening the evidence for the impact
of Ab burden on the structural integrity of the entorhinal cor-
tex. In addition to this main effect of Ab accumulation on
brain structure, we also observed an Ab-induced accelera-
tion of age-related structural change, especially within the
parahippocampal gyrus. Although Ab accumulation did
not exert a similar main effect on cognition as it did on brain
structure within this overall CN cohort, we found evidence
that it was associated with faster age-related decline in
cognitive performance, particularly in the domain of Speed
& Flexibility.
The observed Ab-induced alteration in the entorhinal cor-
tex—detected in both global Ab analyses and colocalized
PiB/MRI analyses—is consistent with other studies
revealing the loss of cortical mass in the entorhinal region,
as a result of amyloid aggregation in the elderly [11,31].
The entorhinal cortex, which is a key afferent to the
hippocampus, has been evidenced as a crucial center ofAD pathology and one of the earliest areas to demonstrate
degeneration [32]. Furthermore, volume of the entorhinal
cortex is a reliable indicator of future decline from mild
cognitive impairment to AD [33,34] and, when tested in
CN samples, is able to better predict future cognitive
decline than structural changes in other medial temporal
regions, including the hippocampus [34,35].
Our correlational analyses of colocalized Ab accumula-
tion and brain structure also elicited an association between
increased amyloid and decreased amygdala volume, which
was not evident in our group analyses. The amygdala is a
mesial temporal structure observed to decrease in mass early
in disease progression, and further exhibits a prominent
volumetric decrease during the latter stages of AD [36].
Amygdala volume is a viable predictor of both future decline
and the severity of decline in early and mild AD, and may be
a better predictor than volume of the hippocampus [36–41].
In studies of AD individuals, the amygdala has been found to
correlate with performance in the domains of memory,
orientation, and recall [38,39]. Similar results have been
Fig. 2. Amyloid beta (Ab) burden accelerates age-related brain structural changes. The plots depict predicted values derived from the regression equation (cir-
cles), with the line of best linear fit overlaid. Red circles/line 5 Ab1 group, blue circles/line 5 Ab2 group.
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amygdala volume consistently associated with more
advanced cognitive decline. It is noteworthy that, although
statistical significance in tests of the effect of colocalized
Ab on brain structure was only reached for the entorhinal
cortex and amygdala, a general trend for increased Ab toTable 3
Main effect of Ab on cognition*
Cognitive domain Ab2, n 5 74 Ab1, n 5 35 P value
Verbal Ability 0.15 (0.11) 20.05 (0.16) .330
Visuospatial Ability 0.35 (0.11) 0.11 (0.16) .229
Speed & Flexibility 0.07 (0.09) 20.16 (0.14) .193
Working Memory 0.17 (0.14) 20.11 (0.21) .282
Verbal Learning & Memory 20.15 (.12) 20.17 (0.18) .938
Immediate Memory 20.14 (0.12) 20.17 (0.19) .905
Abbreviation: Ab, amyloid b.
*All values are estimatedmean (standard error), adjusted for age, sex, and
education.track with decreased brain structural integrity was
observable across all the ROIs examined. This suggests
a rather pervasive effect of Ab burden on brain morphom-
etry, although this interpretation needs to be made with
caution given the rather modest magnitude of the observed
correlations.
Our findings also suggest that Abmay accelerate the age-
related loss of brain tissue in the parahippocampal gyrus.
This is interesting because the parahippocampal gyrus
encompasses the entorhinal cortex and, like the entorhinal
cortex, is an early induction site for AD-related neurodegen-
eration [43]. Thus, our findings with respect to Ab’s main ef-
fect on cortical thickness and its acceleration of age-related
cortical thinning are quite convergent, jointly corroborating
prior neuropathological studies that have shown the
parahippocampal-entorhinal strip to be highly susceptible
to the AD degenerative cascade [32,43–46]. Similar to
our colocalized PiB/MRI analyses, although only the
parahippocampal gyrus neared statistical significance in
Fig. 3. Amyloid beta (Ab) burden accelerates age-related cognitive decline. The plots depict predicted values derived from the regression equation (circles),
with the line of best linear fit overlaid. Red circles/line 5 Ab1 group, blue circles/line 5 Ab2 group.
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related cortical thinning, there was a general tendency for
increased Ab to be associated with faster age-related cortical
thinning across the other ROIs examined. This supports the
notion that even ostensibly mild Ab aggregation might not
be innocuous, perhaps becoming more pernicious with the
passage of time [47].
Understanding the linkage between Ab and cognition is
of great importance to the study of AD [48]. The evidence
for an association between Ab accumulation and cognition
in CN cohorts is, however, mixed. Several cross-sectional
studies in CN individuals have found no evidence of a rela-
tionship between Ab accumulation and cognition [13–15],
but some do find an association, primarily within the
domain of episodic memory [16,17]. A meta-analysis of
studies investigating Ab-cognition effects in CN individuals
[49] suggested that although there is a modest association
between amyloid accumulation and cognition, effect sizes
in areas other than episodic memory and global cognition
are small. Chetelat and colleagues [47] suggested that the
variations in the observed effect of Ab on cognition may
be due to differences in the underlying characteristics of
the study samples, especially in age and APOE ε4 status.
In the present study, we found that, despite the apparent
Ab-induced degeneration of the entorhinal cortex and amyg-
dala—two structures critical to episodic memory—there
were no statistically significant main effect of Ab on mem-
ory or other cognitive functions, although the Ab1 group
consistently exhibited lower cognitive test scores than the
Ab2 group. Still, the effects of Ab on cognition were notinconsequential, as we discovered an enhancing effect of
Ab on age-related cognitive decline, particularly in Speed
& Flexibility, which is a cognitive function that is highly
vulnerable to aging effects [50]. Fig. 3 demonstrates that,
in four of the six cognitive domains tested, Ab1 individuals
exhibit a marked decline in cognitive performance with
increasing age, whereas Ab2 individuals do not exhibit
such a decline. This acceleration of “normal” age-related
changes might represent an important approach to the study
of Ab’s effect on cognition, especially in a relatively young
cohort that is only starting to accumulate Ab.
A key limitation of this study is its cross-sectional nature.
Although we used statistical tests of interactions between
age and Ab rating to approximate the longitudinal effects
of Ab burden on brain structure and cognition, a truly pro-
spective design with serial imaging and cognitive data would
have enabled us to better track the progression of structural
and cognitive changes among individuals with versus
without Ab burden. As the WRAP cohort is ongoing, and
additional imaging and cognitive data are being collected,
we will be uniquely positioned to investigate such questions
in the future. Second, we determined cerebral amyloidosis
via qualitative ratings. Although this approach has potential
clinical value (patients are likely to be more interested in
whether their PiB scans are indicative of AD versus whether
their PiB binding is 1.2) and has established precedence in
the literature (for an excellent review, see Chetelat et al.
[47]), there is a possibility that we might have made different
observations had we used a quantitative approach such as by
averaging PiB uptake in select ROIs. Similarly, although our
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on brain structure made our enquiry focused and hypothesis
driven, it may have resulted in a failure to detect findings that
were outside the examined ROIs. In addition, although Free-
Surfer has been shown to yield segmentations that are reli-
able and concordant with manual measurements [51], we
cannot entirely exclude the possibility that there might
have been some variation in its performance across subjects
within our sample. Finally, although our analyses overall
showed that Ab has a measurable, detrimental impact on
brain structure and cognitive function, many of the tests
did not attain statistical significance at the set threshold
(i.e., P 5.05). This might reflect inadequate power on our
part to statistically detect these changes that are, arguably,
only starting to occur and thus relatively subtle in magni-
tude. Future studies with larger sample sizes would be help-
ful in further testing this study’s objectives.
In summary, this study found that increased Ab burden is
associated with deleterious changes in brain morphometry
and cognition in a late to middle-aged, CN cohort with
risk factors for AD. These findings, and those from other
groups [7,10,31,34], provide evidence that the temporal
window between Ab deposition and the inception of
neurodegenerative changes might be narrower than
currently thought [1–3]. Further longitudinal analyses will
help us better understand the prognostic value of Ab
deposition within this relatively young and risk-enriched
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1. Systematic review: We searched PubMed using the
terms: “amyloid,” “amyloid burden,” “amyloid depo-
sition,” “PiB,” “cortical thickness,” “brain volume,”
“brain morphometry,” “brain structure,” “cognition,”
“cognitive function,” and “Alzheimer’s disease” or
“dementia.”
2. Interpretation: The relationship between amyloid b
(Ab) accumulation and brain morphometric mea-
sures/cognition in preclinical Alzheimer’s disease
(AD) is attracting considerable scientific interest.
This study adds to the current knowledge base, by
showing that increased Ab is associated with an ac-
celeration of deleterious age-related changes in
brain morphometry and cognition in a middle-aged,
asymptomatic cohort at risk for AD. These findings
suggest that the temporal lag between Ab deposition
and the initiation of neurodegenerative/cognitive
changes might be narrower than currently thought.
3. Future directions: Continued follow-up of our cohort
will help us better understand the prognostic value of
Ab deposition within this relatively young and risk-
enriched cohort.References
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